BR112022018173A2 - Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo - Google Patents
Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmoInfo
- Publication number
- BR112022018173A2 BR112022018173A2 BR112022018173A BR112022018173A BR112022018173A2 BR 112022018173 A2 BR112022018173 A2 BR 112022018173A2 BR 112022018173 A BR112022018173 A BR 112022018173A BR 112022018173 A BR112022018173 A BR 112022018173A BR 112022018173 A2 BR112022018173 A2 BR 112022018173A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
COMPOSTO DA FÓRMULA (I) OU UM SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA, COMPOSTO PARA O USO E USO DE UM COMPOSTO DA FÓRMULA (I) OU UM SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO. A invenção se refere a compostos da Fórmula (I): (I) ou sais farmaceuticamente aceitáveis dos mesmos, em que R1, R2, R7 e anel A têm qualquer um dos significados acima no presente documentos definidos na descrição; o processo para sua preparação; as composições farmacêuticas que contêm os mesmos e seu uso no tratamento de doenças mediadas por KCC2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062989104P | 2020-03-13 | 2020-03-13 | |
PCT/EP2021/056393 WO2021180952A1 (en) | 2020-03-13 | 2021-03-12 | Fused pyrimidine compounds as kcc2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022018173A2 true BR112022018173A2 (pt) | 2022-10-25 |
Family
ID=74874882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022018173A BR112022018173A2 (pt) | 2020-03-13 | 2021-03-12 | Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo |
Country Status (24)
Country | Link |
---|---|
US (1) | US20230151013A1 (pt) |
EP (1) | EP4103566B1 (pt) |
JP (1) | JP2023517680A (pt) |
KR (1) | KR20220152319A (pt) |
CN (1) | CN115298182A (pt) |
AU (1) | AU2021234134A1 (pt) |
BR (1) | BR112022018173A2 (pt) |
CA (1) | CA3171192A1 (pt) |
CL (1) | CL2022002386A1 (pt) |
CO (1) | CO2022012884A2 (pt) |
DK (1) | DK4103566T3 (pt) |
ES (1) | ES2962136T3 (pt) |
FI (1) | FI4103566T3 (pt) |
HR (1) | HRP20231314T1 (pt) |
HU (1) | HUE064037T2 (pt) |
IL (1) | IL296265A (pt) |
LT (1) | LT4103566T (pt) |
MX (1) | MX2022011354A (pt) |
PE (1) | PE20230106A1 (pt) |
PL (1) | PL4103566T3 (pt) |
PT (1) | PT4103566T (pt) |
RS (1) | RS64823B1 (pt) |
SI (1) | SI4103566T1 (pt) |
WO (1) | WO2021180952A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023107623A2 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Bicyclic heteroarenes and methods of their use |
CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090099195A1 (en) * | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
JP6526065B2 (ja) * | 2014-02-28 | 2019-06-05 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用 |
WO2018217766A1 (en) * | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
US20210254101A1 (en) * | 2018-05-25 | 2021-08-19 | The Children's Medical Center Corporation | Methods for treating spinal cord injury |
-
2021
- 2021-03-12 EP EP21712145.8A patent/EP4103566B1/en active Active
- 2021-03-12 DK DK21712145.8T patent/DK4103566T3/da active
- 2021-03-12 HR HRP20231314TT patent/HRP20231314T1/hr unknown
- 2021-03-12 HU HUE21712145A patent/HUE064037T2/hu unknown
- 2021-03-12 JP JP2022554784A patent/JP2023517680A/ja active Pending
- 2021-03-12 WO PCT/EP2021/056393 patent/WO2021180952A1/en active Application Filing
- 2021-03-12 SI SI202130073T patent/SI4103566T1/sl unknown
- 2021-03-12 CN CN202180020856.3A patent/CN115298182A/zh active Pending
- 2021-03-12 PL PL21712145.8T patent/PL4103566T3/pl unknown
- 2021-03-12 CA CA3171192A patent/CA3171192A1/en active Pending
- 2021-03-12 LT LTEPPCT/EP2021/056393T patent/LT4103566T/lt unknown
- 2021-03-12 PE PE2022001943A patent/PE20230106A1/es unknown
- 2021-03-12 KR KR1020227035465A patent/KR20220152319A/ko active Search and Examination
- 2021-03-12 IL IL296265A patent/IL296265A/en unknown
- 2021-03-12 PT PT217121458T patent/PT4103566T/pt unknown
- 2021-03-12 US US17/911,051 patent/US20230151013A1/en active Pending
- 2021-03-12 RS RS20231022A patent/RS64823B1/sr unknown
- 2021-03-12 FI FIEP21712145.8T patent/FI4103566T3/fi active
- 2021-03-12 BR BR112022018173A patent/BR112022018173A2/pt unknown
- 2021-03-12 ES ES21712145T patent/ES2962136T3/es active Active
- 2021-03-12 MX MX2022011354A patent/MX2022011354A/es unknown
- 2021-03-12 AU AU2021234134A patent/AU2021234134A1/en active Pending
-
2022
- 2022-09-01 CL CL2022002386A patent/CL2022002386A1/es unknown
- 2022-09-09 CO CONC2022/0012884A patent/CO2022012884A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2022002386A1 (es) | 2023-04-28 |
DK4103566T3 (da) | 2023-10-30 |
LT4103566T (lt) | 2023-11-10 |
EP4103566B1 (en) | 2023-10-04 |
WO2021180952A1 (en) | 2021-09-16 |
MX2022011354A (es) | 2022-11-30 |
PT4103566T (pt) | 2023-11-09 |
WO2021180952A9 (en) | 2021-12-16 |
KR20220152319A (ko) | 2022-11-15 |
IL296265A (en) | 2022-11-01 |
FI4103566T3 (fi) | 2023-10-20 |
AU2021234134A1 (en) | 2022-11-03 |
JP2023517680A (ja) | 2023-04-26 |
EP4103566A1 (en) | 2022-12-21 |
US20230151013A1 (en) | 2023-05-18 |
HUE064037T2 (hu) | 2024-03-28 |
CO2022012884A2 (es) | 2022-10-11 |
PL4103566T3 (pl) | 2024-02-05 |
RS64823B1 (sr) | 2023-12-29 |
PE20230106A1 (es) | 2023-01-25 |
CN115298182A (zh) | 2022-11-04 |
SI4103566T1 (sl) | 2024-04-30 |
HRP20231314T1 (hr) | 2024-02-16 |
ES2962136T3 (es) | 2024-03-15 |
CA3171192A1 (en) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
BRPI0908353B8 (pt) | composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica | |
UY39029A (es) | Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2 | |
BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
BRPI0416283A (pt) | compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos | |
BRPI0608245A2 (pt) | compostos; processo para a sua fabricação; composições farmacêuticas; método para o tratamento e/ou prevenção de doenças que estejam associadas à modulação de receptores de sst subtipo 5 e uso dos compostos | |
BRPI0410037B8 (pt) | inibidores de fosfatidilinositol 3-cinase, sua composição farmacêutica, e seu uso | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BRPI0517634A (pt) | derivado de tiazol ou um derivado farmaceuticamente aceitável do mesmo, processo para a preparação de um composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
BRPI0516972A (pt) | composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto | |
BR112022018173A2 (pt) | Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo | |
BRPI0406717A (pt) | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção | |
BR112018073524A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição. | |
BRPI0408767A (pt) | inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv | |
BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
BR112021019817A2 (pt) | Compostos de pirrol | |
BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
BRPI0606997A2 (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa) e utilização dos compostos | |
BR112021002565A8 (pt) | Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto | |
AR124036A1 (es) | Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición | |
BR0214937A (pt) | Processo de preparação de derivados de equinocandina | |
BR0104471A (pt) | Compostos de ciclobutenodiona, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos | |
BR112022003562A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos |